What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?

被引:9
作者
Boers, M. [1 ]
Buttgereit, F. [2 ]
Saag, K. [3 ]
Alten, R. [4 ]
Grahn, A. [5 ]
Storey, D. [6 ]
Rice, P. [7 ]
Kirwan, J. [8 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, NL-1007 MB Amsterdam, Netherlands
[2] Charite, D-13353 Berlin, Germany
[3] Univ Med, Schlosspk Klin, Berlin, Germany
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Horizon Pharma, Deerfield, IL USA
[6] DPS Ltd, Cookham, England
[7] Premier Res, Naperville, IL USA
[8] Univ Bristol, Bristol, Avon, England
关键词
RELEASE PREDNISONE; CIRCADIAN-RHYTHMS; GLOBAL ASSESSMENT; STIFFNESS; REMISSION; DETERMINANTS; REEVALUATION; DURATION; EFFICACY; CRITERIA;
D O I
10.1002/acr.22592
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveLittle is known about the relationship between morning symptoms of rheumatoid arthritis (RA) and measures of disease activity currently used to assess RA. Information available from the Circadian Administration of Prednisone in Rheumatoid Arthritis (CAPRA-2) study was used to investigate these relationships. MethodsCAPRA-2 included 350 patients with RA who were symptomatic despite treatment with disease-modifying antirheumatic drugs, randomized 2:1 to additional treatment with a 5-mg daily dose of delayed-release prednisone or placebo. Pearson's correlations were used to evaluate the relationships between change from baseline in symptoms (duration of morning stiffness, severity of morning stiffness, and intensity of pain on waking) and measures of disease activity (the American College of Rheumatology 20% improvement criteria [ACR20], the Disease Activity Score in 28 joints [DAS28], and the Health Assessment Questionnaire disability index). Correlations were defined as weak (<0.3), moderate (0.3-0.7), or strong (>0.7). ResultsThere was a strong correlation between the severity of morning stiffness and the intensity of morning pain (Pearson's correlation 0.91, P < 0.001). There was a weak correlation between the duration of morning stiffness and measures of disease activity (0.24-0.28), with moderate correlations between the severity of morning stiffness or intensity of pain on waking and DAS28 or ACR20 scores (0.44-0.48). Severity of morning stiffness showed less variability and a greater effect size than did duration of morning stiffness. ConclusionMorning symptoms and measures of disease activity show weak to moderate correlations. Severity of morning stiffness showed less variability and greater effect size than did duration of morning stiffness. These findings suggest that severity is the preferred construct to measure the impact of morning stiffness in patients with RA, information that is not fully captured in the RA core set.
引用
收藏
页码:1202 / 1209
页数:8
相关论文
共 50 条
  • [41] Relationship between disease activity level and physical activity in rheumatoid arthritis using a triaxial accelerometer and self-reported questionnaire
    Toyoshima, Yoichi
    Yajima, Nobuyuki
    Nemoto, Tetsuya
    Namiki, Osamu
    Inagaki, Katsunori
    BMC RESEARCH NOTES, 2021, 14 (01)
  • [42] Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis
    Rodriguez-Polanco, Elaudi
    Al Snih, Soham
    Kuo, Yong-Fang
    Millan, Alberto
    Rodriguez, Martin A.
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (05) : 657 - 665
  • [43] Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index
    Hoque, Anika
    Steultjens, Martijn
    Dickson, Diane M.
    Hendry, Gordon J.
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (10) : 1807 - 1817
  • [44] Perspectives of colon-specific drug delivery in the management of morning symptoms of rheumatoid arthritis
    Jain, Swapnil N.
    Patil, Sanjay B.
    INFLAMMOPHARMACOLOGY, 2023, 31 (01) : 253 - 264
  • [45] Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity
    Karpouzas, George A.
    Strand, Vibeke
    Ormseth, Sarah R.
    RMD OPEN, 2018, 4 (01):
  • [46] Relationships between serum 25-hydroxycalciferol, vitamin D intake and disease activity in patients with rheumatoid arthritis - TOMORROW study
    Matsumoto, Yoshinari
    Sugioka, Yuko
    Tada, Masahiro
    Okano, Tadashi
    Mamoto, Kenji
    Inui, Kentaro
    Habu, Daiki
    Koike, Tatsuya
    MODERN RHEUMATOLOGY, 2015, 25 (02) : 246 - 250
  • [47] A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
    Curtis, Jeffrey R.
    Churchill, Melvin
    Kivitz, Alan
    Samad, Ahmed
    Gauer, Laura
    Gervitz, Leon
    Koetse, Willem
    Melin, Jeffrey
    Yazici, Yusuf
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (12) : 3104 - 3112
  • [48] Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
    Paul, Stephane
    Marotte, Hubert
    Kavanaugh, Arthur
    Goupille, Philippe
    Kvien, Tore K.
    de Longueville, Marc
    Mulleman, Denis
    Sandborn, William J.
    Vande Casteele, Niels
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (04): : 743 - 751
  • [49] Serum Levels of Beta-2 Microglobulin in Rheumatoid Arthritis Patients and its Relationship with Disease Activity: Can it be used as a Disease Activity Marker?
    Dincer, Ayse Bahar Kelesoglu
    Torgutalp, Murat
    Yayla, Mucteba Enes
    Guloksuz, Emine Gozde Aydemir
    Sezer, Serdar
    Yurteri, Emine Uslu
    Okatan, Ilyas Ercan
    Turgay, Murat
    Kinikli, Gulay
    Ates, Askin
    AKTUELLE RHEUMATOLOGIE, 2021, 46 (03) : 297 - 304
  • [50] Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study
    Lee, Yvonne C.
    Bingham, Clifton O.
    Edwards, Robert R.
    Marder, Wendy
    Phillips, Kristine
    Bolster, Marcy B.
    Clauw, Daniel J.
    Moreland, Larry W.
    Lu, Bing
    Wohlfahrt, Alyssa
    Zhang, Zhi
    Neogi, Tuhina
    ARTHRITIS CARE & RESEARCH, 2018, 70 (02) : 197 - 204